Licensing · MENA · Announced 28 Sept 2026
Undisclosed Chinese manufacturer → Newbury Pharmaceuticals
Sweden's Newbury Pharmaceuticals secured exclusive 10-year rights to register and sell a 40-product injectable hospital portfolio, led by anti-infectives, from an unnamed Chinese manufacturer in Iraq. Terms undisclosed.
Parties: Undisclosed Chinese manufacturer (China) → Newbury Pharmaceuticals (Sweden)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Iraq only; exclusive, 10 years; products sold under Newbury's label or own brands
- Therapeutic area
- Multi-therapy
- Assets
- Cefepime; Ceftriaxone; Meropenem; Vancomycin; Tranexamic acid; IV paracetamol
- Announced
- 28 Sept 2026
Our analysis
Why This Matters
Newbury Pharmaceuticals, through its subsidiary Newbury Pharmaceuticals S.A. , announced on 28 September 2026 that it has secured exclusive rights to register, market, and sell a portfolio of 40 hospital products in Iraq. The rights come from an unnamed, established Chinese pharmaceutical manufacturer following a multi-year collaboration. The agreement runs for ten years, and the products will be sold under Newbury’s own brand names.
The full analysis is free to read with a work email on this page.